Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/15/2005US20050201962 Modified Porphyran
09/15/2005US20050201956 Lupeol anti-tumor agent and uses thereof
09/15/2005US20050201955 Use of compatible solutes for inhibiting the release of ceramides
09/15/2005US20050201952 Treatment and prevention of viral hepatitis infections
09/15/2005US20050201950 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
09/15/2005US20050201949 Pharmaceutical formulations
09/15/2005US20050201947 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
09/15/2005US20050201938 Method for selectively inhibiting ghrelin action
09/15/2005US20050201932 Drug delivery using Polymeric immunoglobulin receptor (pIgR) which when cleaved has a stalk region which remains attached to the cell and a secretory component (SC) which exists in an organ of interest in several forms
09/15/2005US20050201888 Sterilization process
09/15/2005DE4126475B4 13-Dihydro-3'-(2-Alkoxy-4-morpholinyl)anthracycline, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Zusammensetzungen 13-dihydro-3 '- (2-alkoxy-4-morpholinyl) anthracyclines, processes for their preparation, their use and compositions containing them
09/15/2005DE102004010153A1 Perorale Vitamin E-enthaltende Zubereitungen Oral vitamin E-containing preparations
09/15/2005DE102004009931A1 Use of specific 2-substituted benzamides for treating and preventing cardiac insufficiency, especially where caused by diastolic dysfunction, act by inhibition of the Kv1.5 potassium channel
09/15/2005DE102004009835A1 New 4-heterocyclyl-benzamide derivatives, useful as antithrombotic agents for treating or preventing e.g. deep vein thrombosis or reocclusion after angioplasty, are inhibitors of factor Xa and other serine proteases
09/15/2005DE102004009783A1 Hyperverzweigte Stärkefraktion, Verfahren zu ihrer Herstellung und ihre Konjugate mit pharmazeutischen Wirkstoffen Hyperbranched starch fraction, processes for their preparation and their conjugates with active pharmaceutical ingredients
09/15/2005DE102004009185A1 New hygrophorone derivatives useful as biocides, antibiotics, fungicides, enzyme inhibitors, disinfectants or wood preservatives
09/15/2005DE102004008375A1 Use of synergistic combination of ascorbate and a sympathomimetic for topical treatment of inflammation of respiratory mucosa, particularly where caused by viral infection
09/15/2005DE102004004972B3 Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Heterocyclic-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, to processes for their preparation and their use as medicaments
09/15/2005CA2599727A1 Composition and process for post-etch removal of photoresist and/or sacrificial anti-reflective material deposited on a substrate
09/15/2005CA2598687A1 Flavonoids
09/15/2005CA2559295A1 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
09/15/2005CA2559188A1 Hyaluronic acid-methotrexate conjugate
09/15/2005CA2558813A1 Pharmaceutical composition comprising cxcr3 inhibitor
09/15/2005CA2558810A1 Methods for altering insulin secretion
09/15/2005CA2558753A1 Polymorphisms in the epidermal growth factor receptor gene promoter
09/15/2005CA2558721A1 Screening method for emulators of neural activity and digestive system using gpr35
09/15/2005CA2558715A1 Process for inhibiting cell proliferation
09/15/2005CA2558667A1 Antisense oligonucleotides for inhibiting the formation of metastases in cancer
09/15/2005CA2558600A1 A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4
09/15/2005CA2558532A1 Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
09/15/2005CA2558497A1 Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
09/15/2005CA2558416A1 Use of lipid conjugates in the treatment of disease
09/15/2005CA2558380A1 Combination therapy with glatiramer acetate and riluzole
09/15/2005CA2558375A1 Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
09/15/2005CA2558278A1 Diaryl-substituted five-membered heterocycle derivative
09/15/2005CA2558274A1 Cycloalkanopyridine derivative
09/15/2005CA2558263A1 Nanocell drug delivery system
09/15/2005CA2558262A1 Rnai-based therapeutics for allergic rhinitis and asthma
09/15/2005CA2558211A1 Bicyclic and bridged nitrogen heterocycles
09/15/2005CA2558198A1 Crystalline composition containing escitalopram oxalate
09/15/2005CA2558167A1 Amino acid derivatives
09/15/2005CA2558150A1 Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenetic alopecia
09/15/2005CA2558109A1 Heteroaryl-fused pyrazolo derivatives
09/15/2005CA2558082A1 Ester derivatives of rhein and their therapeutic use
09/15/2005CA2557989A1 Sulfated oligosaccharide derivatives
09/15/2005CA2557988A1 3-pyridinium methylcephem compound
09/15/2005CA2557976A1 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
09/15/2005CA2557968A1 Method and composition for burned skin
09/15/2005CA2557927A1 Structured triglycerides and emulsions comprising same
09/15/2005CA2557858A1 Amino cyclopropane carboxamide derivatives as bradykinin antagonists
09/15/2005CA2557857A1 Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
09/15/2005CA2557814A1 Compositions and methods for treating diseases
09/15/2005CA2557766A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
09/15/2005CA2557758A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
09/15/2005CA2557676A1 Synergistic anti-inflammatory pharmaceutical compositions and methods of use
09/15/2005CA2557667A1 Aryl substituted purine analogues
09/15/2005CA2557645A1 Caspase inhibitors and uses thereof
09/15/2005CA2557643A1 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
09/15/2005CA2557634A1 Stable capsule preparation
09/15/2005CA2557610A1 Use of carboxypeptidase g for combating antifolate toxicity
09/15/2005CA2557581A1 Inhibitors of dna methylation in tumor cells
09/15/2005CA2557435A1 Stable pharmaceutical solution formulations for pressurized metered dose inhalers
09/15/2005CA2557354A1 Alkaloid formulations
09/15/2005CA2557322A1 Inhibitors of hepatitis c virus ns3 protease
09/15/2005CA2557320A1 Fused heterocyclic derivatives for prevention or treatment of hyperglycemia
09/15/2005CA2557304A1 Ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
09/15/2005CA2557303A1 Use of thiadiazole urea derivatives
09/15/2005CA2557302A1 Pyridinamide derivative as kinase inhibitors
09/15/2005CA2557301A1 Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
09/15/2005CA2557285A1 Adenosine receptor agonists
09/15/2005CA2557270A1 Pyrrole-derivatives as factor xa inhibitors
09/15/2005CA2557268A1 Indazole derivatives and pharmaceutical compositions containing them
09/15/2005CA2557263A1 Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency
09/15/2005CA2557262A1 Medicament for preventing and/or treating ischemic cardiovascular disease
09/15/2005CA2557260A1 Triptolide lactone ring derivatives as immunomodulators and anticancer agents
09/15/2005CA2557161A1 Pharmaceutical composition comprising pimobendan
09/15/2005CA2557160A1 Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
09/15/2005CA2556991A1 Crystalline forms of valacyclovir hydrochloride
09/15/2005CA2556969A1 Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
09/15/2005CA2556946A1 Pyrrolopyrimidine derivatives
09/15/2005CA2556829A1 Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
09/15/2005CA2556790A1 Enzyme-prodrug therapy for prosthetic joint repair
09/15/2005CA2556771A1 Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
09/15/2005CA2556692A1 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
09/15/2005CA2556386A1 Isothiourea derivatives
09/15/2005CA2556383A1 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies
09/15/2005CA2556380A1 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
09/15/2005CA2555921A1 Therapeutic calcium phosphate particles and methods of making and using same
09/15/2005CA2555890A1 Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues
09/15/2005CA2555712A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
09/15/2005CA2555616A1 New therapeutic use for a group of sulphated polysaccharides
09/15/2005CA2555612A1 Compositions and methods for the treatment and clinical remission of psoriasis
09/15/2005CA2555161A1 Novel 4-benzimidazol-2-yl-pyridazin-3-one derivatives
09/15/2005CA2555050A1 8-[3-amino-piperidin-1-yl]-xanthine derivatives, the production thereof and the use in the form of a dpp-iv inhibitor
09/15/2005CA2554772A1 Crystal forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
09/15/2005CA2552907A1 Beta-ketoamide compounds having an mch-antagonistic effect and medicaments containing said compounds
09/14/2005EP1574579A2 Outer surface proteins, their genes, and their use
09/14/2005EP1574575A1 GLUCOSE AND/OR FRUCTOSE TRANSPORTER NaGLT1 AND ITS GENE
09/14/2005EP1574574A1 Exon 1-beta of pdgf receptor alpha gene and utilization thereof
09/14/2005EP1574569A1 Three-dimensional structure of lipocalin-type prostaglandin d synthase and utilization of the same
1 ... 4542 4543 4544 4545 4546 4547 4548 4549 4550 4551 4552 4553 4554 4555 4556 4557 4558 4559 4560 4561 4562 ... 7860